SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Worldwide Diversified Holdings, Inc. (OTCMKTS:WNTR) continues to assess additional opportunities within technology and cybersecurity space to diversify its product portfolio. It is also assessing opportunities in the financial industry that will create additional value for shareholders.

The highlights

Worldwide Diversified reported that they have extended the Dutch Tender proposal until September 2016. Till that time they will continue to buy back shares to enhance shareholder value. The firm has obtained, as of June 2016, a total of around 52.82 million common shares priced between $0.0001 and $0.01.

Worldwide Diversified has also obtained a total redemption of 650 million previously released common shares, to minimize the shares outstanding count. The firm is implementing this plan to minimize the count of outstanding shares without opting for reverse stock split process.

The buzz

In May, the company released financial report for the quarter closing March 31, 2016. The total assets jumped to over $34 million in the reported period compared to $33.90 million for the same quarter ending March 31, 2015. Net income surged by 115% to $158,794 over the comparable period, a year earlier. Worldwide Diversified asset value was $0.01c a share in the reported period.

The company has previously reported a Tender Offer to buy up to 2 billion of its common shares priced in a range of $0.0001 to $0.01 per share. It is also assessing other measures to enhance shareholder value. The other plans include evaluating a proposal for listing its stock on other exchanges, which will help realize its asset value.

Worldwide Diversified has recorded, as of March 31, 2016; a total of over 202 million common shares priced in between $0.0001 and $0.01 a share. It has received redemption of 650 million previously released common shares, to minimize the count of outstanding shares. During this announcement, it was confirmed that the shares were not adjusted to the issued and outstanding shares till the time tender offer is closed.

China’s Robust Organic Food Market Reinvigorates Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) Growth Prospects

The exponential growth of China’s organic food market is helping affirm Lotus Biotech growth prospects. The biotech company is now planning to accrue a substantial amount of market share in the multi-billion industry as more people turn to organic foods to service their needs.

Food safety issues in the recent past have resulted in an upsurge in demand for organic food, the total value of organic food production having more than tripled between 2007 and 2012. Given the robust growth in the space, Lotus Biotech remains bullish about generating a substantial amount of revenue going forward given the plans it has put in place.

The company has been busy inking deals with other biotechnology companies as it looks to develop more organic food products. The company is also using the collaboration to pursue growth opportunities on the global scene even as it continues to depend on China for growth.